Literature DB >> 12569556

Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.

Toshiyuki Sasagawa1, Robert C Rose, Khadijeh K Azar, Akemi Sakai, Masaki Inoue.   

Abstract

Oncogenic human papilloma virus (HPV) infection is the most important risk factor for developing cervical cancer. It is known that serum antibody responses against these viruses are associated with persistent infection. We conducted an epidemiological study of 627 women to detect cervical mucosal immunoglobulin (Ig)A and IgG responses to oncogenic HPV capsids. Antibody reactivity and cervical HPV infection genotypes were examined by enzyme-linked immunosorbent assay (ELISA) using HPV types 16, 18, 31, and 45 virus-like particles, and a polymerase chain reaction-based method, respectively. HPV infection was defined as being positive for HPV DNA. Multivariate analysis revealed that a mucosal IgA response was associated with the HPV infection, whereas the IgG response was associated with high-grade cervical squamous intraepithelial lesions (SIL)/squamous cell cancer (SCC) and subject age (40-49 years). IgA was positive in 72% of women with oncogenic HPV infections, whereas IgG was positive in 64% of women with high-grade SIL/SCC. The longitudinal study demonstrated that the IgA response was elicited earlier than the IgG response, and the IgG response was barely induced in the preclinical HPV infection. However, once an IgG response was induced, it persisted longer after HPV clearance. The mucosal IgA response reflects current HPV infection, whereas an IgG response may be induced with the development of cervical lesions. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12569556     DOI: 10.1002/ijc.10939

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Chris J L M Meijer; Hester E de Melker; Guy A M Berbers; Fiona R M van der Klis
Journal:  Hum Vaccin Immunother       Date:  2012-11-13       Impact factor: 3.452

2.  Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women.

Authors:  Elham Hassen; Devendra Bansal; Randa Ghdira; Anouar Chaieb; Hedi Khairi; Abdelfattah Zakhama; Sami Remadi; Johan Hoebeke; Ali A Sultan; Lotfi Chouchane
Journal:  J Transl Med       Date:  2020-07-29       Impact factor: 5.531

3.  Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

Authors:  Ralph-Sydney Mboumba Bouassa; Hélène Péré; Camélia Gubavu; Thierry Prazuck; Mohammad-Ali Jenabian; David Veyer; Jean-François Meye; Antoine Touzé; Laurent Bélec
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 4.  Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature.

Authors:  Jade Pattyn; Severien Van Keer; Wiebren Tjalma; Veerle Matheeussen; Pierre Van Damme; Alex Vorsters
Journal:  Papillomavirus Res       Date:  2019-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.